Incentive Formularies Have Minimal Effect


Researchers at Harvard Medical School wanted to determine the effect of changes in drug benefit design on pharmaceutical use and spending. They observed prescription drug spending by plan and member and also formulary compliance, including use of generic medications and mail-order fulfillment.

Eligible enrollees were younger than 64, had prescription drug coverage provided by the health plan, and were drawn from 11 states.

Members who switched from a two-tier to a three-tier formulary had a decrease in total drug spending of 5 percent to 15 percent. Changing to an incentive formulary with higher copayments was accompanied by a small but inconsistent decrease in the use of nonformulary selections and a concomitant rise in both generic and "formulary preferred" utilization.

"Other studies suggest that there's a tremendous behavioral response when patients switch ... to three-tier formularies," says Bruce E. Landon, MD, MBA, lead author and associate professor of medicine and health care policy at Harvard Medical School. "There is a definite measurable response, but the response isn't as big as it's been touted to be."

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.